Canagliflozin-Induced Diabetic Ketoacidosis

Introduction: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are relatively new antihyperglycemic agents that lower renal glucose reabsorption. They are used as adjunctive therapy to standard diabetes treatment. Case Report: We present the case of a 62-year-old woman with a past medical history of type 2 diabetes mellitus and sudden-onset diabetic ketoacidosis (DKA). Use of canagliflozin, a SGLT-2 inhibitor, was determined to be the cause of the DKA. The patient ultimately recovered after 5 days in the intensive care unit. She was changed to long- and short-acting insulins and instructed to avoid canagliflozin. Conclusion: Although SGLT-2 inhibitors are effective at lowering a patient’s hemoglobin A1C, physicians must be aware of the rare but dangerous potential adverse effect of inducing DKA. This article reports an illustrative case and presents a review of the literature.

• Publication year

  2016

• Venue

  Journal of Investigative Medicine High Impact Case Reports

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/2324709616663231PMID 27635409PMCID 5011300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium–Glucose Cotransporter 2 Inhibitor Treatment

  2016cited by this paper
• Diabetic Ketoacidosis With Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes

  2016cited by this paper
• Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern

  2016cited by this paper
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

  2016cited by this paper
• SGLT inhibition and euglycaemic diabetic ketoacidosis.

  2015cited by this paper
• Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

  2015cited by this paper
• Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet

  2015cited by this paper
• Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors

  2015cited by this paper
• A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.

  2015cited by this paper
• Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

  2015cited by this paper
• Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

  2014cited by this paper
• Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

  2013cited by this paper
• 의사 간호사 communication

  2011cited by this paper
• US Department of Health and Human Services gives states wider latitude in choosing services to be covered by Medicaid.

  2001cited by this paper

• SGLT‐2 inhibitors and high‐dose acarbose as potential high‐risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series

  2024cites this paper
• Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials

  2023cites this paper
• Case Report: Euglycemic diabetic ketoacidosis led by empagliflozin: A case report and literature review

  2022cites this paper
• SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review

  2022cites this paper
• Real world study of short term efficacy, safety, and tolerability of canagliflozin 100 mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer.

  2021cites this paper
• Evolving evidence of diabetic ketoacidosis in patients taking sodium glucose cotransporter 2 inhibitors.

  2020cites this paper
• The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i

  2020influential citation
• A review of recent developments in the pharmacological prevention and treatment of endocrinopathic laminitis

  2020cites this paper
• Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report

  2019cites this paper
• SGLT2 inhibitors: are they safe?

  2018cites this paper
• Sodium‐glucose co‐transporter‐2 inhibitors and diabetic ketoacidosis: An updated review of the literature

  2018cites this paper
• Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy—an emerging problem and solutions offered by diabetes technology

  2017cites this paper
• Insulin and other hypoglycemic drugs

  2017cites this paper
• Acid-base and electrolyte disorders associated with the use of antidiabetic drugs

  2017cites this paper
• Canagliflozin lowers blood sugar, but does it also lower cardiovascular risk? Maybe not.

  2017cites this paper